viewC4X Discovery Holdings PLC

C4X Discovery Holdings says strong progress across the portfolio as commercial discussions continue

C4X Discovery Holdings PLC's (LON:C4XD) chief executive Clive Dix talks to Proactive London about taking over as the interim chair of the UK Vaccine Taskforce following the departure of Kate Bingham.

Dix goes on to discuss how this appointment will impact C4X, explaining "if you look at what we've achieved at C4X in the last year, I don't think you'll see a blemish on that productivity".

Moving on to the latest results, Dix says "it's been a really good year", with progress on all four of the key programmes including treatment of opioid dependence Indivior, the inflammatory bowel disease drug, the psoriasis programme and the treatment of IBD.

After the £15mln raise earlier in the year, Dix says the company is "financially in a very very secure position".

With reference to their four key programmes, Dix says it's about the "right data, the right time, to get to the right partner".

Quick facts: C4X Discovery Holdings PLC

Price: 33 GBX

Market: AIM
Market Cap: £74.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...


C4X Discovery CEO welcomes start of Indivior trial and outlines new...

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence. The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix...

on 25/8/20

2 min read